scholarly journals Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies

2021 ◽  
Vol 27 (10) ◽  
pp. 1438-1446
Author(s):  
Emmeline C Academia ◽  
Caroline M Mejías-De Jesús ◽  
Julia S Stevens ◽  
Lily Y Jia ◽  
Tuyen Yankama ◽  
...  
Keyword(s):  
Health System ◽  
Specialty Pharmacy ◽  
Oral Oncolytics

Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies

2020 ◽  
Vol 77 (14) ◽  
pp. 1118-1127
Author(s):  
Colleen C McCabe ◽  
Meagan S Barbee ◽  
Marley L Watson ◽  
Alyssa Billmeyer ◽  
Collin E Lee ◽  
...  
Keyword(s):  
Health System ◽  
Multiple Regression ◽  
Patient Adherence ◽  
Medical Center ◽  
Academic Medical Center ◽  
Medication Possession Ratio ◽  
Primary Objective ◽  
Wilcoxon Test ◽  
Tumor Type ◽  
Specialty Pharmacy

Abstract Purpose The primary objective of the study described here was to compare rates of patient adherence to anticancer medications filled at an internal health system specialty pharmacy (HSSP) vs external specialty pharmacies. The primary outcome was the medication possession ratio (MPR), and the secondary outcomes included proportion of days covered (PDC), and time to treatment (TTT). Methods A retrospective chart review was conducted to compare the MPR, PDC, and TTT for patients who received oral anticancer therapy using prescriptions claim data. A t test or Wilcoxon test was used to explore the effect of demographic and other factors on adherence and TTT. A multiple regression model with backward elimination was used to analyze significant factors to identify covariates significantly associated with the outcomes. Results Of the 300 patients screened for study inclusion, 204 patients whose records had complete MPR and PDC data and 164 whose records had TTT data were included in the analysis. There were significant between-group differences in mean MPR and mean PDC with patient use of the HSSP vs external pharmacies (1.00 vs 0.75 [P < 0.001] and 0.95 vs 0.7 [P < 0.001], respectively). Pharmacy type (P = 0.024) and tumor type (P = 0.048) were significantly associated with TTT. Conclusion The multiple regression analysis indicated that oncology patients who filled their anticancer medication precriptions at an internal HSSP at an academic medical center had significantly higher adherence, as measured by MPR and PDC, and quicker TTT than those who filled their prescriptions at an external specialty pharmacy.

scholarly journals Implementation of an internal check of oral oncolytics: a single-center, specialty pharmacy safety initiative

2019 ◽  
Vol 8 (sup1) ◽  
pp. 25-25
Author(s):  
Mitchell Hughes ◽  
Richard Kriska ◽  
Gregory Strong ◽  
Jennifer Chung ◽  
Lily Nguyen ◽  
...  
Keyword(s):  
Single Center ◽  
Internal Check ◽  
Specialty Pharmacy ◽  
Oral Oncolytics ◽  
Safety Initiative

Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative

2019 ◽  
Vol 76 (17) ◽  
pp. 1296-1304 ◽  
Author(s):  
Nisha B Shah ◽  
Jacob A Jolly ◽  
Sara N Horst ◽  
Megan Peter ◽  
Heather Limper ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Health System ◽  
Bowel Disease ◽  
Biologic Therapy ◽  
Clinical Care ◽  
Disease Status ◽  
Quality Measures ◽  
Pharmacy Benefit Manager ◽  
Inflammatory Bowel ◽  
Specialty Pharmacy

Abstract Purpose The development of a tool to measure medication safety, therapeutic efficacy, and other quality outcomes in patients receiving self-injectable biologic therapy for the management of inflammatory bowel disease (IBD) at a health-system specialty pharmacy is described. Summary Through a collaborative initiative by pharmacists, gastro-enterologists, and representatives of a pharmacy benefit manager and a pharmaceutical company, a set of clinical and specialty pharmacy quality measures was developed. The clinical measures are intended for use in assessing patient safety, disease status, treatment efficacy, and healthcare resource utilization during 3 assessments (pre-treatment, on-treatment, and longitudinal). The specialty pharmacy measures can be used to assess medication adherence, medication persistence, specialty pharmacy accreditation, and patient satisfaction. The proposed quality measures provide a foundation for evaluating the quality of IBD care and improving patient outcomes within a health-system specialty pharmacy. Future efforts to validate and implement the tool in clinical practice are planned. Conclusion The proposed quality measures provide a foundation for future inquiry regarding the appropriateness and feasibility of integrating the measures into clinical care. Further work is needed to implement and validate these quality measures and determine their impact in optimizing health outcomes.

Providing uninterrupted oral oncolytic therapies during the COVID-19 pandemic.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 226-226
Author(s):  
Edward Arrowsmith ◽  
Rachel L. Mitchell ◽  
Jack L. Taylor ◽  
Stephen Matthew Schleicher ◽  
Natalie R. Dickson ◽  
...  
Keyword(s):  
Insurance Coverage ◽  
Home Delivery ◽  
Pharmacy Staff ◽  
Cost Share ◽  
Grant Support ◽  
Number Of Patients ◽  
Specialty Pharmacy ◽  
Time Periods ◽  
Comparison Table ◽  
Oral Oncolytics

226 Background: Uninterrupted utilization of oral oncolytics is critical to maximizing safety and efficacy of cancer treatment. The COVID-19 pandemic presented numerous challenges to delivering a continuous and safe supply of oral oncolytics to patients with cancer including potential loss of insurance coverage, patient lost income making copays more difficult, remote pharmacy staffing difficulties, and logistical challenges in safely distributing drug to cancer patients. Tennessee Oncology has an in-house Specialty Pharmacy that utilizes home delivery of oral oncolytics while coordinating care with providers during changing patient situations. Methods: We analyzed patients who received an oral oncolytic from our pharmacy in two periods: January-May 2019 and January-May 2020. We compared the aggregate patient copay amounts during these periods, the number of patients who utilized copay assistance or foundational financial support. For insights on continuation we also assessed the medication possession ratios (MPR, the sum of the day’s supply for all fills of a given drug in a particular period divided by the number of days in that period) during these time periods for five of our most commonly dispensed drugs. Results: The aggregate patient copay was similar between the two time periods. A 22% increase in the utilization of copay cards indicated patient’s insurance coverage was sustained. We also observed a 12% increase in the number of patients utilizing foundation support for prescriptions filled. MPRs for five commonly dispensed oral oncolytics were unchanged during COVID-19. Conclusions: Our in-house specialty pharmacy maintained delivery of oral oncolytics during the COVID-19 pandemic. Patient cost share was contained by our pharmacy staff proactively utilizing copay cards for all eligible patients and diligently securing foundational grant support. The pharmacy interventions allowed for affordability, uninterrupted pharmacy operations, and consistent medication supply. This led to continued medication adherence. MPR for the 5 top dispensed medications was consistent in a year-on-year comparison. [Table: see text]

scholarly journals Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy

2021 ◽  
Vol 27 (7) ◽  
pp. 882-890
Author(s):  
Megan E Peter ◽  
Autumn D Zuckerman ◽  
Josh DeClercq ◽  
Leena Choi ◽  
Cameron James ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Health System ◽  
Integrated Health ◽  
Specialty Pharmacy

scholarly journals Specialty Pharmacy Services: Preparing for a New Era in Health-System Pharmacy

2015 ◽  
Vol 50 (9) ◽  
pp. 834-839 ◽  
Author(s):  
Blake Shay ◽  
Les Louden ◽  
Bonnie Kirschenbaum
Keyword(s):  
Health System ◽  
Pharmacy Services ◽  
New Era ◽  
Specialty Pharmacy

scholarly journals Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System

2017 ◽  
Vol 23 (8) ◽  
pp. 815-820 ◽  
Author(s):  
Autumn Bagwell ◽  
Tara Kelley ◽  
Alicia Carver ◽  
Jennifer B. Lee ◽  
Brandon Newman
Keyword(s):  
Health System ◽  
Patient Care ◽  
Pharmacy Services ◽  
Academic Health ◽  
Specialty Pharmacy

Decoding gene therapy: Current impact and future considerations for health-system and specialty pharmacy practice

2021 ◽  
Author(s):  
Scott L Canfield
Keyword(s):  
Gene Therapy ◽  
Health System ◽  
Health Systems ◽  
Pharmacy Practice ◽  
The United States ◽  
Gene Therapies ◽  
Novel Treatments ◽  
Engagement Strategies ◽  
Clinical Benefits ◽  
Specialty Pharmacy

Abstract Purpose To provide health systems with baseline knowledge on existing and pipeline gene therapy treatments, including considerations that health-system pharmacies and specialty pharmacy programs may reference when evaluating and implementing services around gene therapies. Summary Advancements in research and biotechnology have recently led to the development and launch of the first commercially available gene therapy treatments in the United States. These treatments have the ability to significantly alter and even effectively cure diseases. Alongside these significant advances and clinical benefits, these therapies present unique challenges due to their cost and complexity. Given the large number of additional gene therapy treatments that are currently in late-stage clinical development, stakeholders across the healthcare industry must increasingly adapt and ready themselves to meet these challenges. The diagnosis and treatment of patients with diseases being targeted by gene therapies largely occurs within health systems, and judging by the gene therapy pipeline, this trend is likely to continue. To prepare for these novel treatments, health systems must understand and consider the methods in which gene therapies are developed, procured, reimbursed, administered, and monitored. Conclusion The future of health-system pharmacy practice must include comprehensive gene therapy services and stakeholder engagement strategies to ensure patients have access to these life-changing treatments.

Sign in / Sign up

Export Citation Format

Share Document